Delcath Systems (NASDAQ:DCTH) released its quarterly earnings results on Tuesday. The company reported ($0.60) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.49, Fidelity Earnings reports.
DCTH stock traded down $0.17 during mid-day trading on Thursday, hitting $12.25. The company had a trading volume of 16,844 shares, compared to its average volume of 251,406. The firm has a market cap of $50.43 million, a PE ratio of -0.01 and a beta of 0.83. Delcath Systems has a 12 month low of $6.06 and a 12 month high of $25.18. The stock’s fifty day moving average price is $19.20 and its two-hundred day moving average price is $17.45.
Several equities analysts have commented on DCTH shares. BTIG Research started coverage on shares of Delcath Systems in a research report on Tuesday, January 5th. They set a “buy” rating and a $23.00 target price on the stock. Zacks Investment Research raised Delcath Systems from a “hold” rating to a “buy” rating and set a $19.00 price target for the company in a research report on Tuesday, January 26th. Finally, Canaccord Genuity began coverage on Delcath Systems in a research report on Monday, March 15th. They issued a “buy” rating and a $24.00 price objective on the stock. Five investment analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and a consensus price target of $21.00.
Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company's lead product candidate is the melphalan hydrochloride for injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver.
Further Reading: What are Bollinger Bands?
Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.